In addition, Ruzzo et al. [17] reported an improved overall survival in patients with elevated let-7a within a KRAS mutant colorectal cancer population treated with anti-EGFR therapy, suggesting a tumor inhibitory role for let-7a in KRAS-activated tumors. Here, KRAS is linked to colorectal cancer.